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ABSTRACT
Objective: To review the use of evidence in the market approval process,
reimbursement, and price control mechanisms for medicines and medical
devices in China, Japan, and Singapore.
Methodology: Documentary reviews relevant to public health policy and
management by government authorities.
Results: Drug regulatory authorities play a vital role in the market autho-
rization process of medical technologies. The approval criteria in the three
countries are similar to those of the US Food and Drug Administration and
many other countries, whose core measures are efﬁcacy, safety, and quality,
along with risk-based analyses in China and Singapore. All established the
national drug list (Japan) or lists (China and Singapore) for reimbursement.
Although Japan reimburses any drugs listed, China and Singapore selec-
tively reimburse regarding the types of the list. The cost-effectiveness is
utilized for prioritization of new drugs listed in Singapore. Japan controls
the price by government, whereas Singapore keeps market liberalism, and
China maintains a mixture of both.
Conclusion: All three countries have established their own mechanisms,
but cost-effectiveness requirements have not been fully introduced yet,
partially applied to the reimbursement processes in Singapore.
Keywords: health reform, medical technology, drug regulation, pricing,
reimbursement, cost effectiveness.
Introduction
This article was synthesized from three country papers presented
at the 3rd ISPOR Asia Paciﬁc Conference in Seoul, Korea on
September 6, 2008. The objective of the papers presentation was
to review the use of evidence in the market approval process,
reimbursement, and price control mechanisms for medicines and
medical devices in China, Japan, and Singapore, which is con-
sidered to be at an intermediate stage of employing cost-
effectiveness requirements in the government policies.
China
To build a “Harmonious Society” as the central goal for China’s
development, the state health reform embarks on a major initia-
tive of “Health China 2020,” aiming at providing a universal
medical insurance coverage for all citizens by 2020. Under the
current state health reform plan, public ﬁnance will allocate
additional RMB850 billion funds to health care for the next 3
years.
During the rapid economic transition from 1978 through
2009, the Chinese health system has also undergone substantial
reforms in recent years. Two distinguished issues are worth
noting. First, the total health-care share of GDP is about 4.7%.
Although this is a low percentage relative to international stan-
dard, the private portion paid out of pocket (OOP) is more than
50% in recent years [2], among the very top tire of countries with
the highest OOP payment.
Second, the health delivery system is still highly dominated by
the state-owned providers, accounting for 90% of the total hos-
pitals nationwide. They challenge with a major dilemma to
balance providing low-priced services with accounting for no
more than 10% of total average budget because of the reduced
public funds.
With the rapidly inﬂated medical inputs and upgraded tech-
nology, public hospitals are left with little options but with
greater incentives to seek cross-subsidy revenues by supplying
more proﬁtable services. As a result, pharmaceutical use accounts
for nearly 50% of the total health expenditures.
Japan
Universal coverage is a feature of health insurance in Japan,
established in 1961. About 5000 units of insurers are catego-
rized: Employees’ Health Insurance (EHI) makes up 60%,
whereas National Health Insurance (NHI) for nonemployees
makes up 40%. Fee-for-service is the principle of payment with
copayment of 30% on-site, according to the fee and reimburse-
ment rules biennially revised by the MHLW. The aging society
makes NHI ﬁnancially weaker year by year, shifting the elderly at
a higher risk from EHI to NHI. The National Medical Expendi-
ture is USD300 billions, 8% of Japanese GDP, with an increment
of USS10 billion per year. Four challenges to reform have been
implemented by the MHLW: 1) long-term care insurance since
2000; 2) diagnosis procedure combination since 2003; 3) The
Healthcare Systems Reform Act in July 2006; and 4) proposal of
the New Pricing System Reform since 2007.
Singapore
Singapore has a hybrid system of health-care delivery. Private
general practitioners (GPs) provide 80% of the primary health-
care services, whereas the government polyclinics provide the
remaining 20%. For the more costly hospital care, it is the
reverse situation, with 80% of the hospital care being provided
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by the public sector and the remaining 20% by the private sector
(There are 13 public sector and private sector hospitals, respec-
tively. The private hospitals are, however, much smaller in size
compared with the public sector hospitals.) [3]. Patients are free
to choose providers within the hybrid health-care delivery
system. The aim of the Ministry of Health (MOH) is to ensure
that patients receive health care that is appropriate to their needs
across the continuum of care based on current evidence and
clinical knowledge. To achieve this, evidence is employed in
various stages of health-care decision-making.
The NHI Systems
China
Currently, China has four major medical insurance schemes
available as follows.
The Urban Employment Basic Medical Insurance
(UEBMI). The UEBMI is a mandatory insurance scheme for
formal sector employees in urban areas. Started in 1998, UEBMI
schemes are organized featuring with social pooling account and
medical savings account. Funding for the UEBMI comes from
premium contributions by employers for about 6% to 8% and by
employees for 2% of the beneﬁciary base salary, respectively [4].
Currently, the UEBMI covers more than 200 million urban-
employed population. On the balance sheet, the UEBMI has
accumulated fund surplus signiﬁcantly more than its expenses.
The recurrent surplus indicates that the risk pooling capacity is
large enough to support an increase in beneﬁt payments without
undermining the scheme sustainability. Given these conditions
and the health reform effort, the Ministry of Human Resources
and Social Security (MHRSS) is expected to take actions aiming at
bringing down the surplus by either raising the rate of beneﬁt
payment or enlisting some newer drugs on the program formulary.
The New Rural Cooperative Medical Insurance (NRCMI). In
2003, the State Council began to reestablish the NRCMI for
farmers. The NRCMI policy speciﬁcations include 1) a govern-
ment subsidy of an RMB 80 premium contribution conditional
on an individual contribution of RMB 20 annually; 2) insurance
coverage primarily for inpatient care and major outpatient
expenses; 3) voluntary enrollment on a family basis; and 4) risk
pooling and administration at the county level under the local
bureaus of health.
The NRCMI has grown very rapidly in the last few years,
covering nearly 850 million people or more than 90% of the total
rural population at present. The NRCMI has made a signiﬁcant
progress in providing beneﬁts to the rural population. National
statistics show an increase of 15.9% for total health cost and
45.3% up for insurance expenses per enrollee, suggesting an
increasing share of the cost burden paid by the insurance.
Although the NRCMI was started to reimburse inpatient ser-
vices, more and more local NRCMI programs have begun to
cover outpatient services. Some pilot NRCMI schemes also cover
physical examinations and offer ﬁxed subsidies for labor and
delivery services.
The Urban Resident Basic Medical Insurance (URBMI). In July
2007, the State Council initiated the URBMI for urban residents.
After the pilot experiments in 79 cities, the URBMI has now
covered over 100 million urban residents. Similar to the NRCMI,
the current URBMI policy settings include government contribu-
tion of an RMB 80 premium per enrollee, voluntary participa-
tion, insurance against major illnesses treated at inpatient
facilities, and a low level of reimbursement due to limited pooling
capacity compared with the UEBMI. Based on an evaluation
study by Lin et al. [5], the poor and those with previous use of
inpatient services are more likely to enroll in the URBMI. These
two disadvantaged groups also seem to gain more in terms of
access to care and a reduction of their ﬁnancial burden. In
addition, the disadvantaged groups also tend to be more satisﬁed
with URBMI policies.
The URBMI yields two policy implications. First, the State
Council is committed to increasing public ﬁnancing for popula-
tion health, with social medical insurance as the main approach
of health-care ﬁnancing. Second, the newly initiated URBMI,
together with the UEBMI and the NRCMI, serves as a milestone
step toward universal health insurance coverage for China by
2010.
Private Medical Insurance (PMI). PMI covers approximately
6% of urban dwellers and 8% of rural individuals. The revenue
of the “PMI” market in China is about 30 billion RMB in 2006
as compared to the annual income of the UEBMI of 180 billion
RMB. Although relatively small, PMI has gained a foothold and
could expand relatively rapidly consistent with the increase in
disposable income, increasing urbanization, and demand for
quality service, provided appropriate supportive policies are in
place. With PMI as a strong complement/supplement to the
UEBMI, the ﬁnancial burden on the government would be
reduced, thereby freeing up public funds to be used in rural areas
or for those with lower income levels.
Despite growth, PMI still has a very low penetration rate and
only accounts for 2% of total health expenditure compared with
20% globally. From a societal perspective, PMI may better help
mobilize additional resources within a ﬁnancially constrained
health-care system.
Japan
Japan has a public insurance system for health care that has
been covering the whole population since 1961. Even though
insurance bodies consist of employer-based, region-based, and
mutual aid association-based organizations, health insurance
coverage and pricing decisions are uniformly determined by the
government.
According to the national medical expenditure report of
2006, total annual medical expenditure in Japan was 33 trillion
yen (approximately US$330 billion).
Singapore
The Singapore health-care ﬁnancing system is based on indi-
vidual responsibility, coupled with government subsidies, to keep
basic health care affordable. Patients are expected to pay part of
the cost of medical services that they use and to pay more when
they demand a higher level of service. For example, in public
sector hospitals, a C class patient enjoys 80% of subsidies while
A class patients pay full fees. The difference is in physical
amenities—a C class patient is housed in an eight-bedded cubicle,
whereas an A class patient has a single room. The clinical care
provided is not dependent on the ward class but on the patient’s
clinical needs. Patients choose the ward class where they wish to
be admitted [6].
Individuals are encouraged to take responsibility for their
own health by saving for medical expenses. Under the Medisave
scheme (introduced in 1984), all working persons are required by
law to set aside 6.5% to 9% of their income into their personal
Medisave account which can be used to pay for hospitalization
expenses incurred by them or their immediate family members
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[7]. MediShield, a catastrophic illness insurance scheme intro-
duced in 1990, was designed to help individuals meet medical
expenses from major or prolonged illnesses [8]. Medifund, an
endowment fund set up by the government in 1993, acts as a
safety net of last resort for those who are truly indigent [9].
Therefore, no Singaporeans will be denied access into the health-
care system or turned away by the public hospitals because of
inability to pay.
Mechanisms and Evidence Used in
Market Authorization
China
The State Food and Drug Administration (SFDA) serves as the
government regulatory authority to approve all medical drugs
and devices to be marketed in China. New and generic applica-
tions of domestically manufactured products must be submitted
through the local provincial regulatory agencies for initial assess-
ments. Follow-up reviews on clinical trials and ﬁnal approvals
are directed at the central SFDA [10]. With the exception of
certain imported over the counter (OTC) products, applications
for imported products are submitted directly to the SFDA. The
waiting time for the approval of a new drug application is usually
between 1 to 2 years.
The approval criteria of the SFDA are similar to those of the
US Food and Drug Administration (FDA) and many other coun-
tries, whose core measures are efﬁcacy, safety, and quality evalu-
ations of the outcome of preclinical and clinical studies, along
with risk-based analyses [11]. Recently, under the health reform
initiatives with increasing calls for cost containment, some dis-
cussions are engaged on cost-effectiveness as a possible measure
to be considered for priority settings.
A major difference exists between the approvals of the SFDA
and the US FDA. When approving a product by granting a
marketing license, the SFDA requires the licensee to have a
manufacturing license for the product. In other words, a drug
marketer must also be a drug manufacturer [11]. In contrast, in
the United States, a drug marketer can outsource manufacturing
to others. This special approval requirement of the SFDA faces
increasing challenges, as more and more traditional manufactur-
ers fail to discover new products, whereas many R&D-oriented
innovators lack the manufacturing capability, resulting in a 40%
idling rate of China’s drug manufacturing capacity [12].
Amid mounting domestic and international pressure, the
SFDA is taking encouraging steps to improve its approval policy
and practice to make them more compatible with the interna-
tional standards. These steps include the adoption of the Drug
Master File system, the Pre-Approval Inspection requirement,
and the emphasis of Quality by Design and Good Review Prac-
tice [10]. There have also been welcome discussions on global
simultaneous development to speed up multicenter clinical
studies [13].
Japan
All drugs and devices must be approved by the Ministry of
Health, Labour and Welfare in Japan. In 2004, the Pharmaceu-
ticals and Medical Devices Agency (PMDA) was established as
an independent body to consult the approval process and review
the submitted materials as well as pharmacovigilance. The
PMDA has three main roles. One is to review new drug appli-
cations from the viewpoint of safety, efﬁcacy, and quality. Clini-
cal trial data that demonstrate efﬁcacy and safety are required for
application. The PMDA also gives advices to each company
regarding clinical trial designs. Sometimes clinical trial data in
other countries are accepted with bridging studies that include
pharmacokinetic/pharmacodynamics studies among Japanese
people.
Singapore
The Health Sciences Authority (HSA), a statutory board under
the MOH, safeguards public health by ensuring that health prod-
ucts (e.g., drugs, medical devices) in Singapore meet appropriate
standards of safety, efﬁcacy, and quality. It employs a risk-
stratiﬁcation strategy in the regulation of health products with
different regulatory requirements for the range of health products
available here. The requirements for medical devices, for
example, are more detailed and stringent than those for cosmet-
ics because they are generally viewed to be of higher risk.
There is also an array of options available for the registration
of pharmaceutical and biological health products in Singapore
that provides ﬂexibility to companies in planning their regulatory
submissions. For instance, if a product has already been
approved by at least one competent drug regulatory agency the
company can choose an abridged route for registration by sub-
mitting data that have been reviewed by that regulatory agency.
The review takes about 180 working days (excluding stop clock).
There is also a veriﬁcation route for products already evaluated
and approved by at least two of the HSA’s reference drug regu-
latory agencies—the US FDA, Health Canada, Australian Thera-
peutics Goods Administration, European Medicines Agency, and
the UK Medicines and Health Products Regulatory Agency
(“Guidance on Medicinal Product Registration in Singapore”
accessed at http://www.hsa.gov.sg). This offers the quickest turn-
around time of about 60 working days (excluding stop clock).
Those products that have not been approved elsewhere have to
go through full evaluation by the HSA, which can take about 270
working days (excluding stop clock).
Thorough product assessment does not mean the product is
risk-free because the full safety and efﬁcacy proﬁle will only be
known when the drug is used in thousands of patients in the
“real-world” situation. The HSA has thus supplemented the
approval system with a pharmacovigilance system that is able to
detect problems early and enhance the knowledge base related to
the product.
With the emergence of more complex issues, relying on local
knowledge would not be adequate. The HSA has increasingly
collaborated internationally and tapped on external panels of
experts for advice. This also enables potentially more work
sharing between international bodies so as not to duplicate
resources.
Once a health product is allowed entry into the Singapore
market, health-care professionals are free to prescribe them as
required by their patients regardless of whether they are in the
public or private sector.
Mechanisms, Processes, and Evidences Used in
Decisions for Reimbursement
China
Drugs on the national drug list are reimbursable under the three
insurance schemes above. The government introduced the cur-
rently existing reimbursement system in the 1990s, pledging to
update the national drug reimbursement list (NDRL) every 2
years. Presently the NDRL, managed by the MHRSS, covers
about 1027 Western drugs and 823 traditional Chinese medi-
cines (TCMs). The NDRL is separated into two parts: A list (315
Western drugs) and B list (712 Western drugs) and the rest of
TCMs. The A list means “Clinic necessary & effective, wide
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coverage, and lower price.” Most of them are local generics with
100% reimbursement; the B list means “Clinic selective & effec-
tive; premium priced” including brand products and some
imported and/or JVs’ with 10% to 30% patient copayment.
Currently, about 700 compound or 15% of drugs are classiﬁed as
category B and is determined by provincial governments.
The ﬁrst NDRL was issued in 2000 and revised in 2004 when
40% more pharmaceuticals and 90% more TCMs were added
among selected drugs launched before 2003. Currently, there are
a large number of new compounds approved by the SFDA and
are on the market in China but are excluded from reimbursement
as they wait for the next revision. This may impede patient access
to new medicines and disincentivizes new development and
investment in new pharmaceuticals in China. For example, drug
launched since 1997 took an average of 3 years to get on national
drug reimbursement listing compared with an average of 6
months for the United States and France and 3 months for Japan.
China appears to have the longest time lag between product
launch and gaining reimbursement.
The current health reform has proposed to improve criteria
for NDRL inclusion, and in principles they would include fre-
quent clinical need, regional economic conditions, drug usage
patterns, efﬁcacy, efﬁciency, cost-effectiveness, and availability.
Nevertheless, it is a great challenge to implement the criteria
scientiﬁcally in the selection process, which has been much
dependent upon expert opinions. In addition, greater effort has
been made in the recent reform to reinforce the state essential
drug policy, leading to a national essential drug list (EDL). EDL
is intended for the selection of a subset of NDRL drugs, but the
former would be subject to a much higher standard in terms of
safety, effectiveness, cost, and availability measures. Following
the state reform policy, EDL drugs must be fully stocked, used,
and reimbursed as the ﬁrst line for popular diseases at all
community-based primary health facilities and pharmacies.
Based on the most recent policy update, EDL will include around
300 drugs, with about 200 Western medicines and 100 Chinese
medicines.
Japan
Reimbursement decisions are made by the Ministry of Health,
Labour and Welfare. After the approval, pharmaceutical compa-
nies request to the ministry to add the drug to be added to the
positive list for reimbursement by the public insurance system.
The ministry will make decisions upon consultation with medical
societies. Most of the prescription drugs are covered by the
public health insurance scheme, which counts over 15,000 items.
Reimbursement decisions are made no later than 90 days
after approval. For reimbursement decisions, any additional
documents on evidence are not required besides new drug
applications dossier. Nevertheless, since 1992, pharmaceutical
companies have been allowed to attach the results of pharma-
coeonomic studies to the new drug application dossier.
Sakamaki et al. [14] reported the result of the survey on the
dossier with pharmacoeconomic evidence. They picked up all
new drugs that were approved from 1997 to 2000 and asked
each company if it had submitted economic evaluation data.
Among 114 new drugs, 37 (32%) were submitted with economic
evaluation data. The proportion did not differ between Japanese
companies and foreign companies.
In another study Ikeda and Onozuka [15] surveyed the drugs
approved from 2000 to 2002. They revealed that the proportion
was reduced to 23%. In this study the reason why companies did
not attach such data was also asked. The main reason was that
there was no merit to attach pharmacoeconomic data.
Singapore
Subsidies for drugs. Singapore has a Standard Drug List (SDL)
that was established in 1979. Standard drugs are deﬁned as
clinically relevant and cost-effective drugs that are considered as
basic therapies and essential for management of common dis-
eases afﬂicting the majority of patients. Subsidized patients pay
$1.40 per item per week for SDL 1 drugs (essential ﬁrst-line
drugs) and 50% of the selling price of the SDL2 drugs (relatively
more expensive essential drugs). Although there is no subsidy for
nonstandard drugs, subsidized patients can pay for nonstandard
drugs from their Medisave and/or Medishield (inpatients). If they
are unable to pay for these drugs, they can be considered for
ﬁnancial support under Medifund.
An annual call for applications for standard drugs inclusion is
made by the MOH to the public institutions. Applicants are
required to prioritize their applications before submission
(through their respective hospital’s Chairman Medical Board) to
the MOH Drug Advisory Committee (DAC). The prioritization
criteria include therapeutic gaps, line of therapy, disease preva-
lence, type of outcome, affordability of the drug to patients, and
cost-effectiveness. The DAC evaluates the submissions with the
technical assistance of the Pharmaco-economics and Drug Utili-
zation Unit (HSA) (a unit funded by the MOH) and recommends
drug preparations that are suitable for inclusion in the SDL. This
process is conducted regularly to ensure the continued relevance
of the SDL for clinical practice. The DAC also provides guidance
to the MOH on rational prescribing and usage of drugs.
Introduction of new technologies. In 2000, the Health Service
Development Programme (HSDP) was established by the MOH
with the objective of developing new health services and medical
capabilities through the funding of, among others, new cutting-
edge medical technology, which require a period of evaluation.
Since its inception, all proposals for funding under the HSDP
have been required to include evidence to support the use of the
proposed technology, and this is best achieved by submitting an
health technology assessment (HTA) report of the technology.
Role of evidence in policymaking and clinical practice. In addi-
tion to the above examples, HTA is also used in policy develop-
ment. These are most commonly done as rapid reviews, with
more comprehensive reviews done if the topic warrants it.
To provide guidance on evidence-based clinical practices for
important conditions, theMOHhas published 56 clinical practice
guidelines (CPG) (including revisions) to date since the ﬁrst one in
1997. The target audience is primary care doctors. The topics are
selected during an annual prioritization exercise involving stake-
holders (MOH, professional societies like College of Family Prac-
titioners Singapore, Academy of Medicine, and the Singapore
Medical Association). Topics for CPG development are selected
based on national priorities in disease management, public health
impact, potential number of doctors and patients who can beneﬁt,
and utility of guidelines (e.g., condition where there is evidence of
effective treatment but wide variation in practice) [16].
CPGs are developed by multidisciplinary expert workgroups
through evidence-based methodologies. Drafts are sent to rel-
evant professional societies to build consensus and seek endorse-
ment. CPGs are published, launched, and disseminated to all
registered medical practitioners and other relevant professionals.
CPGs are freely available online in various formats (PDF, hand-
held formats). Launches are recorded and slides and speeches are
also available online. Patient versions of the guidelines are also
published.
Decision-Making on Medical Technologies in China, Japan and Singapore S15
The MOH also organizes and carries out training on
evidenced-based medicine (EBM) methods and topics in collabo-
ration with external partners. Training on CPG development and
critical appraisal workshops have also been organized to
promote a culture of evidence-based health care. The ministry
also collaborated with the Singapore Medical Journal to publish
a quarterly newsletter (i.e., TARGET) that highlights recently
published systematic reviews, HTA, CPGs, and EBM topics from
elsewhere. As part of the ministry’s effort to raise the proﬁle of
EBM and HTA, major international conferences, the Health
Technology Assessment International Annual Meeting, and the
Cochrane Colloquium are being held in Singapore in 2009.
Mechanisms, Processes, and Evidence Used in
Decisions on Pricing
China
The National Development and Reform Commission (NDRC)
has been in charge of the pricing of medical drugs and devices
that are included in the drug formularies associated with all
publicly funded insurance programs. Products not covered in the
drug formularies can be determined freely by market forces.
Although drugs included in the state drug formulary list account
for 20% of approximately 10,000 available products, they share
about 60% to 70% of market sales value.
Drug price regulation is jointly administrated by NDRC
agencies at both national and provincial levels. Currently, about
1500 drugs have been classiﬁed as category A, and their pricing
is determined by the NDRC at the national level. About 800 or
15% of drugs are classiﬁed as category B, and their price ceilings
are left to the discretion of provincial governments. In 2005,
pricing regulatory responsibility for OTC drugs was delegated
from the NDRC to provincial pricing bureaus that can set prices
according to local health-care priorities and requirements.
There are two primary drug pricing regulations: 1) uniform
pricing ceiling applicable to generics of meeting good manufac-
turing practice (GMP) standard; and 2) “independent pricing
policy” for speciﬁed pharmaceutical products, largely patented
medicines, off-patent originators, domestic primary generics, and
subsequent generics of obviously superior quality. In 2001, the
NDRC issued regulations, permitting drugs that can demonstrate
a better treatment rate at a lower cost than generics or similar
drugs to apply for independent pricing under a special pricing
system. This system allows companies to request special higher
pricing if they can show signiﬁcant safety and efﬁcacy beneﬁts
compared with similar drugs. The “independent pricing policy”
has played positive roles in motivating manufacturers to improve
drug quality and undergo incremental innovation in recent years.
Since 1998, the NDRC has instituted 27 mandatory retail
price cuts on over 2000 chemical compounds and 300 TCMs. On
average, the price reduction cross therapeutic categories is
around 20%. Nevertheless, the excessive pricing cuts did not
seem to accomplish the intended goal of reducing the total
private out-of-pocket spending in recent years. This is primarily
because a uniform pricing cut was encountered by the lack of a
comprehensive reform in the rational use of medicine, insurance
coverage policy, and the SFDA approval policy for “new” drugs.
For example, for each price cut, manufacturers responded with
launching more “new” drugs, usually branded generics under
changed name, formula, or packaging, whereas “old” drugs were
removed from the market because of low proﬁt margins.
With government pricing interventions, how is the average
price level of pharmaceuticals in China relative to other countries
in Asia? A recent study [17] ﬁnds that the average price of all
drugs in China is about 35% of developed markets and 55% of
Asia/emerging markets. For generics, the relative prices in China
are even lower at about 20% to 30% of comparable drugs in
selected Organization for Economic Cooperation and Develop-
ment (OECD) markets.
Japan
Prescribed drug prices are determined by the government, based
on the opinions of the Central Social Insurance Medical Council
(Chu-I-Kyo). The council consists of seven representatives from
health-care providers, seven from health-care insurers, and six
from public perspective. Medical fee and drug prices are regu-
larly revised every 2 years. Drug price revision is based on the
wholesale price survey. All wholesalers and sampled health-care
providers are surveyed. The price of each drug is set at the mean
wholesale price plus reasonable zone (R-zone). R-zone is thought
to cover the reasonable margin for health-care providers to store
and dispense drugs. It is currently determined as 2% of the
previous price.
For new drugs there are two methods to set base prices. One
is based on comparison with a similar drug. The similar drug is
chosen by means of similarity in efﬁcacy, pharmacology, chemical
structure, medication method, and form. The base price of the
new drug is calculated as the daily expenditure will be equivalent
to the daily expenditure of the similar drug. It seems reasonable
as far as the similar drug is adequately chosen and can be thought
to have equivalent efﬁcacy and safety. Nevertheless, if the new
drug is more effective than the similar drug, the new drug can be
priced higher than the similar drug. It is called “innovative addi-
tion” and “useful addition.” Innovative addition is 50% to
100% of the base price, and it is applied when the new drug is
developed with innovative idea, shows extremely high efﬁcacy or
safety, and contributes to a large improvement in the treatment of
the target disease. Useful addition is 5% to 40% and applied
when a part of the three criteria for innovative drug is achieved.
The second method is applied when there are no similar drugs
to the new drug. In this case the base price will be based on actual
costing data submitted by the pharmaceutical company. Costing
data include costs of research and development as well as costs of
producing and distribution. This rule is just on costing and does
not consider the value of drugs.
After the base price for the new drug is determined, the price
is adjusted by taking the average price of the drug of the United
States, the UK, France, and Germany into account. When the
base price of the new drug is calculated as 50% or higher than
the average price of those countries or the base price is 25% or
lower, the price will be adjusted so that the price difference
between Japan and foreign countries will be smaller.
Singapore
Singapore does not practice price or proﬁt controls, relying
instead on market forces.
Discussion and Conclusion
China
Under the current health-care reform agenda, the development of
a national EDL will be a key component of the state drug policies.
The EDL selection criteria would include the population disease
prevalence, efﬁcacy, safety, and cost-effectiveness of the medical
products. Following the health reform plan, all EDL drugs will be
priced under government control, used as the ﬁrst-line products,
and fully paid by the state insurance programs.
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The reform effort is also intended to curb the overproduction
of generics and to promote a more efﬁcient and systematic pro-
duction of products. It is expected that the subsequent generics
(copies) will be priced on a decreasing scale away from the price
of the ﬁrst generic of that type. Prices for second and third
generics must be set at a certain percentage lower than the price
of the original generic. Moreover, pharmacoeconomics has been
recognized as an economic approach for drug evaluations for
both the NDRC pricing and state EDL policy settings.
Japan
After having reviewed the domestic cost-effectiveness evidence,
Chu-I-Kyo decided to include smoking-cessation therapy in the
coverage list of public health insurance in April 2006 and nicotine
patches in June 2006. It was unusual but might encourage the use
of economic evaluation for health insurance coverage in Japan.
Those several years, there were some positive movements for
spreading pharmacoeonomic studies in Japan. In 2006, educa-
tion periods for pharmacists were extended from 4 to 6 years in
Japan. Some pharmacy schools adopted the pharmacoeconomic
courses in the curriculum. The other landscapes can be observed
in the new pricing and reimbursement methods for drug approval
under discussions in the Japanese government. It has been pro-
posed to the government by the Federation of Pharmaceutical
Manufacturers Association of Japan since 2007.
Singapore
Recommendations in relevant CPGs have been used to develop
systematic, evidence-based chronic disease management proto-
cols at the national level, i.e., diabetes, lipid disorder, hyperten-
sion, stroke, asthma, and chronic obstructive lung disease. These
protocols are complemented by clinical data collection to facili-
tate the monitoring of process compliance by doctors partici-
pating in the Medisave for Chronic Disease Management
Programme (This program was started in October 6). Patients
visiting doctors participating in this program are allowed to use
their Medisave to pay for their outpatient visits. Participating
doctors are required to report to the MOH the care processes
[based on a predetermined list, e.g., HBAic test, eye and foot
check, etc.] that they have provided to their patients.) [18] and
clinical outcomes (e.g., HBAic and LDL results) [19]. These data
are provided back online to GPs comparing their patient demo-
graphics and results with other (deidentiﬁed) GPs in their region
as well as the national aggregate.
As part of the MOH’s effort to ensure appropriate care,
health-care institutions and staff are required to conduct regular
peer reviews of their standards of care through activities such as
pharmaceutical and therapeutics reviews to support rational uti-
lization of drugs. Health-care providers are also monitoring the
provision of evidence-based care for other diseases such as acute
myocardial infarction (e.g., aspirin on admission/discharge, etc.).
Conclusion
In conclusion, all three countries have established their own
mechanisms and processes of market approval, reimbursement,
and pricing control, but cost-effectiveness requirements have not
been fully introduced yet. Singapore uses pharmacoeconomic
evidence for making a reimbursement decision, and some sounds
of reforms can be heard in China and Japan toward the future.
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